// App-Quantinova.ai

TPS9134 : CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.

Researchers

Presenter

  • Joel W. Neal

Principal Investigators

  • Palak Kundu

  • Tomohiro Tanaka

  • Ida Enquist

  • Sid Patel

  • Alessia Balestrini

  • Jin Wang

  • Thomas Newsom-Davis

  • Yasushi Goto

  • Nick Pavlakis

  • Sang-We Kim

Medical Centers

  • Stanford University Cancer Institute, Stanford, CA

  • Genentech, Inc., South San Francisico, CA

  • Genentech, Inc., South San Francisico, CA

  • Gastroenterology, Chelsea and Westminster Hospital, London, United Kingdom

  • National Cancer Center Hospital, Tokyo, Japan

  • Northern Cancer Institute, St Leonards, Sydney, Australia

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of (South), Korea

Locations

  • United Kingdom

  • Japan

  • Australia

  • Republic of South Korea

Companies

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Programmed cell death protein 1

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

  • Kinase Insert Domain Receptor

Drug/Treatment

  • Atezolizumab

  • Cabozantinib

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

Phase

  • III

Study Id's

  • NCT03170960

  • NCT04471428

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved